KR101576328B1 - 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 - Google Patents
당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 Download PDFInfo
- Publication number
- KR101576328B1 KR101576328B1 KR1020127012343A KR20127012343A KR101576328B1 KR 101576328 B1 KR101576328 B1 KR 101576328B1 KR 1020127012343 A KR1020127012343 A KR 1020127012343A KR 20127012343 A KR20127012343 A KR 20127012343A KR 101576328 B1 KR101576328 B1 KR 101576328B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- alkyl
- spiro
- aza
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(CCC[C@]1(CC2)CC[C@]2(C)O)C1=O Chemical compound C*(CCC[C@]1(CC2)CC[C@]2(C)O)C1=O 0.000 description 25
- RWKDOJMAFHROMT-UHFFFAOYSA-N C=C(CC1)CCC1C(OC#[I])=O Chemical compound C=C(CC1)CCC1C(OC#[I])=O RWKDOJMAFHROMT-UHFFFAOYSA-N 0.000 description 1
- JKAXEDYPEARYIE-XQLRXLNXSA-N CC[C@](CC1)(CC[C@]1(CCN1Cc(cc2)cnc2O[C@@H](C)C(C)(C=C)C(C)=C)C1=O)O Chemical compound CC[C@](CC1)(CC[C@]1(CCN1Cc(cc2)cnc2O[C@@H](C)C(C)(C=C)C(C)=C)C1=O)O JKAXEDYPEARYIE-XQLRXLNXSA-N 0.000 description 1
- AYQUIZOELADFLT-UHFFFAOYSA-N COCCC(CC1)(CCC1=C)C(OC#[I])=O Chemical compound COCCC(CC1)(CCC1=C)C(OC#[I])=O AYQUIZOELADFLT-UHFFFAOYSA-N 0.000 description 1
- QWMTUZLOUMALHB-UHFFFAOYSA-N O=C(C(CC1)CCC1=O)OC#[I] Chemical compound O=C(C(CC1)CCC1=O)OC#[I] QWMTUZLOUMALHB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173178 | 2009-10-15 | ||
| EP09173178.6 | 2009-10-15 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147014123A Division KR20140090645A (ko) | 2009-10-15 | 2010-10-12 | 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120074304A KR20120074304A (ko) | 2012-07-05 |
| KR101576328B1 true KR101576328B1 (ko) | 2015-12-10 |
Family
ID=43093680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127012343A Expired - Fee Related KR101576328B1 (ko) | 2009-10-15 | 2010-10-12 | 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 |
Country Status (20)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2411395T3 (da) | 2009-03-23 | 2013-08-05 | Glenmark Pharmaceuticals Sa | Furopyrimidindionderivater som modulatorer for TRPA1 |
| US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
| US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
| CN103319395B (zh) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | 一种4-氟靛红的工业化制备方法及其产品 |
| WO2015103756A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| BR112020008121A2 (pt) | 2017-11-01 | 2020-11-03 | Bristol-Myers Squibb Company | compostos espirocíclico de alqueno como moduladores de receptor farnesoide x |
| AR113820A1 (es) | 2017-11-01 | 2020-06-17 | Bristol Myers Squibb Co | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x |
| JP7264906B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物 |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| BR112020008157A2 (pt) | 2017-11-01 | 2020-10-06 | Bristol-Myers Squibb Company | compostos espirocíclicos como moduladores do receptor farnesoide x |
| CN109369354B (zh) * | 2018-12-15 | 2021-07-09 | 浦拉司科技（上海）有限责任公司 | 一种4,4,4-三氟丁醇的合成方法 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| MX2021009564A (es) | 2019-02-15 | 2021-09-08 | Bristol Myers Squibb Co | Compuestos de amida sustituida utiles como moduladores del receptor de farnesoide x. |
| CA3129619A1 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| MX2021009424A (es) | 2019-02-15 | 2021-09-10 | Bristol Myers Squibb Co | Compuestos de amida sustituida utiles como moduladores del receptor de farnesoide x. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| WO2007127763A2 (en) | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| EA010424B1 (ru) | 2003-12-16 | 2008-08-29 | Пфайзер Продактс Инк. | ПИРИДО[2,3-d]ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 |
| FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2336849T3 (es) * | 2006-04-25 | 2010-04-16 | Eli Lilly And Company | Inhibidores de 11-beta-hidroxiesteroide dehidrogenasa 1. |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 TW TW099134747A patent/TW201118068A/zh unknown
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en active Application Filing
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/ru not_active IP Right Cessation
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/ja not_active Expired - Fee Related
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/zh not_active Expired - Fee Related
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/ko not_active Expired - Fee Related
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/pt not_active IP Right Cessation
- 2010-10-12 PH PH1/2012/500630A patent/PH12012500630A1/en unknown
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/es active IP Right Grant
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/es not_active Application Discontinuation
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/es active Active
- 2010-10-13 AR ARP100103732A patent/AR078619A1/es unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| WO2007127763A2 (en) | 2006-04-25 | 2007-11-08 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
Non-Patent Citations (2)
| Title |
|---|
| Helvetica Chimica Acta, Vol. 60, No. 5, pp. 1650-1656 (1977) |
| Tetrahedron Letters, Vol. 39, No. 46, pp. 8413-8416 (1998) |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012008962A2 (pt) | 2019-09-24 |
| IL218958A0 (en) | 2012-06-28 |
| CA2776457A1 (en) | 2011-04-21 |
| MX2012004311A (es) | 2012-04-30 |
| JP5749272B2 (ja) | 2015-07-15 |
| PH12012500630A1 (en) | 2012-10-22 |
| US20110092512A1 (en) | 2011-04-21 |
| HK1179957A1 (en) | 2013-10-11 |
| US8440710B2 (en) | 2013-05-14 |
| ES2538005T3 (es) | 2015-06-16 |
| AR078619A1 (es) | 2011-11-23 |
| EP2488493B1 (en) | 2015-04-15 |
| RU2012119706A (ru) | 2013-11-20 |
| RU2607080C2 (ru) | 2017-01-10 |
| JP2013507421A (ja) | 2013-03-04 |
| IN2012DN03337A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-10-23 |
| CL2012000937A1 (es) | 2012-09-14 |
| ZA201202613B (en) | 2013-01-30 |
| KR20120074304A (ko) | 2012-07-05 |
| AU2010305859A1 (en) | 2012-06-07 |
| EP2488493A1 (en) | 2012-08-22 |
| CN102858743B (zh) | 2015-06-10 |
| WO2011045292A1 (en) | 2011-04-21 |
| CN102858743A (zh) | 2013-01-02 |
| TW201118068A (en) | 2011-06-01 |
| PE20121732A1 (es) | 2012-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101576328B1 (ko) | 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 | |
| JP6014149B2 (ja) | ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール | |
| KR101438263B1 (ko) | Ｈｓｌ 억제제로서의 아자환형 스파이로유도체 | |
| EP1501803B1 (en) | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | |
| NL1028624C2 (nl) | Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten. | |
| RU2741810C2 (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| JP2013514973A (ja) | チロシンキナーゼ阻害剤 | |
| US9957264B2 (en) | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | |
| CN105593211A (zh) | 吲哚和吲唑衍生物 | |
| TW202412776A (zh) | 作為ｃｄｋ抑制劑之雙環化合物 | |
| JP2008510728A (ja) | ムスカリン受容体のモジュレーター | |
| CN103415506B (zh) | 作为用于治疗糖尿病的hsl抑制剂的仲-羟基环己基衍生物 | |
| JPWO2007007890A1 (ja) | Ｎ−ジヒドロキシアルキル置換２−オキソイミダゾール誘導体 | |
| KR20140025411A (ko) | Hsl 억제제로서의 신규 아자스피로데칸온 화합물 | |
| KR20140011335A (ko) | 아자스피로데카논 화합물 | |
| KR20140090645A (ko) | 당뇨병 치료에 유용한 ｈｓｌ 억제제로서의 스파이로-축합된 사이클로헥산 유도체 | |
| WO2014017342A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
| HK1179957B (en) | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes | |
| KR20130128366A (ko) | 아자사이클릭 화합물 | |
| HK1190706B (en) | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| A107 | Divisional application of patent | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20181204 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20181204 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |